Implication of fibrate therapy for homocysteine

被引：5

作者：

Chan, N

Chan, JCN

机构：

[1] UCL, EURODIAB, London WC1E 6BT, England

[2] Chinese Univ Hong Kong, Prince Wales Hosp, Dept Clin Pharmacol, Shatin, Peoples R China

来源：

LANCET | 1999年 / 354卷 / 9185期

关键词：

D O I：

10.1016/S0140-6736(05)75416-7

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1208 / 1209

页数：2

共 5 条

[1]

Aarsand AK, 1998, J INTERN MED, V244, P169

[2] Plasma homocysteine is related to albumin excretion rate in patients with diabetes mellitus:: a new link between diabetic nephropathy and cardiovascular disease? [J].

Chico, A ;

Pérez, A ;

Córdoba, A ;

Arcelús, R ;

Carreras, G ;

de Leiva, A ;

González-Sastre, F ;

Blanco-Vaca, F .

DIABETOLOGIA, 1998, 41 (06) :684-693

[3] Serum homocysteine increases after therapy with fenofibrate or bezafibrate [J].

Dierkes, J ;

Westphal, S ;

Luley, C .

LANCET, 1999, 354 (9174) :219-220

[4]

Giltay EJ, 1998, ATHEROSCLEROSIS, V139, P197

[5] Hyperhomocysteinemia is associated with an increased risk of cardiovascular disease, especially in non-insulin-dependent diabetes mellitus - A population-based [J].

Hoogeveen, EK ;

Kostense, PJ ;

Beks, PJ ;

MacKaay, AJC ;

Jakobs, C ;

Bouter, LM ;

Heine, RJ ;

Stehouwer, CDA .

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (01) :133-138

← 1 →